The present clinical prognostic parameters, such as prostate-specific antigen (PSA), Gleason score (GS), and clinical or pathological tumor stage, with limitations in the differentiation of the biological heterogeneity of tumors, are unable to accurately estimate the risk of aggressive prostatic tumors. Here, KLK3 is linked to prostate neoplasm.